Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?

• Pharma’s reflections on recent in vivo CAR-T and TCE deals, what data was valuable when clinical data was minimal?
• Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
• Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology

Speakers:

Frank Brennan

Senior Director

UCB

Kevin White

Executive Director - Venture Fund

Boehringer Ingelheim

Shawn Davis

Chief Executive Officer

Liberate Bio

John Gerecitano

Head of Oncology Research & Development

Sana Biotechnology

Weihao Xu

Founder & Chief Executive Officer

Kali Therapeutics